Kenvue (NYSE:KVUE) Price Target Raised to $18.00

Kenvue (NYSE:KVUE) had its target price lifted by Barclays from $17.00 to $18.00 in a report released on Monday morning,Benzinga reports. Barclays currently has an equal weight rating on the stock.

Other equities research analysts have also issued reports about the stock. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Jefferies Financial Group cut their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. UBS Group reduced their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price objective on Kenvue in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.23.

Kenvue Trading Down 0.1%

Shares of Kenvue stock opened at $16.71 on Monday. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The company has a market capitalization of $32.01 billion, a P/E ratio of 22.28, a P/E/G ratio of 2.44 and a beta of 0.71. The company has a fifty day moving average of $16.53 and a 200 day moving average of $20.15.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. During the same period in the previous year, the business earned $0.28 earnings per share. The business’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be issued a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Institutional Investors Weigh In On Kenvue

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KVUE. Salomon & Ludwin LLC bought a new position in shares of Kenvue during the 3rd quarter valued at approximately $25,000. NBT Bank N A NY boosted its stake in Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC increased its position in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the last quarter. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue in the first quarter valued at $30,000. Finally, Golden State Wealth Management LLC raised its stake in shares of Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.